10-K: SenesTech, Inc. Reports 2023 Financial Results and Outlines Strategic Growth Initiatives

SenesTech, Inc. released its 2023 annual report, highlighting a focus on commercializing its fertility control products, ContraPest and Evolve, while navigating financial challenges.

Summary

• SenesTech, Inc. is focused on managing animal pest populations, particularly rats, through fertility control products.
• The company's main products are ContraPest, a liquid bait, and Evolve, a soft bait, both designed to reduce rat reproduction.
• ContraPest is registered in all 50 U.S. states, while Evolve is authorized for sale in 30 states.
• The company reported a net loss of $7.7 million for 2023, compared to a $9.7 million loss in 2022.
• Revenue increased to $1.2 million in 2023 from $1.0 million in 2022, driven by growth in agribusiness, commercial, and distributor markets.
• The company's gross profit was $539,000 in 2023, up from $464,000 in 2022.
• Research and development expenses decreased to $1.2 million in 2023 from $1.9 million in 2022.
• Selling, general, and administrative expenses decreased to $7.0 million in 2023 from $8.3 million in 2022.
• The company has an accumulated deficit of $129.9 million and cash and cash equivalents of $5.4 million as of December 31, 2023.
• SenesTech anticipates needing additional funding to continue operations and achieve profitability.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive revenue growth and a reduction in losses, the company's ongoing financial challenges, need for additional funding, and risks associated with commercialization and regulatory approvals temper the overall sentiment. The company is making progress but faces significant hurdles.

Positives

• Revenue increased by 17% year-over-year, indicating growing market acceptance of the company's products.
• The company's net loss decreased by 20% year-over-year, showing progress in controlling expenses.
• Gross profit increased by 16.2% year-over-year, indicating improved profitability.
• The company has expanded its market reach by securing authorization to sell Evolve in 30 states.
• The company has successfully navigated a reverse stock split to maintain its Nasdaq listing.

Negatives

• The company continues to operate at a loss, with a net loss of $7.7 million in 2023.
• The company has an accumulated deficit of $129.9 million, highlighting its ongoing financial challenges.
• The company's cash and cash equivalents are $5.4 million, which may not be sufficient to fund operations for an extended period.
• The company is dependent on additional financing to continue operations and achieve profitability.
• The company's manufacturing operations are located in a single location, which could be disrupted.

Risks

• The company's success is dependent on the successful commercialization of ContraPest and Evolve.
• The company may not achieve adequate market acceptance for its products.
• The company will require additional capital to fund its operations.
• The company may be unable to establish and maintain an effective sales force and marketing infrastructure.
• The company's products may be misused, harming its reputation and leading to liability suits.
• The company is operating in a period of economic uncertainty and capital markets disruption.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable.
• The company depends on key personnel and may be harmed if they are unable to retain, attract, and integrate qualified personnel.
• The company has limited suppliers and a critical ingredient for ContraPest is currently sourced from China.
• The company's technology may be found to infringe third-party intellectual property rights.
• The company may be subject to legal proceedings that could result in significant harm.
• The company has not fully assessed its internal control over financial reporting.
• Privacy breaches and other cybersecurity risks could negatively affect the company's reputation and business.
• The company has incurred significant operating losses and anticipates continuing to do so.
• The company may not be able to comply with all applicable listing requirements of The Nasdaq Capital Market.
• The company's reverse stock splits may decrease the liquidity of the shares of its common stock.
• Raising additional capital may cause dilution to existing stockholders.
• The company's share price is volatile, which could subject it to securities class action litigation.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for at least the next 12 months and will need additional funding to continue to fund operations, achieve profitability and become cash flow positive. The company also expects to introduce an additional product during 2024.

Management Comments

• The most effective, long-term way to manage rats is by using a combination of tools that work together to magnify the efficacy of the pest management protocol.
• The addition of a fertility control product to an IPM program has demonstrated improved efficacy of more than 90% with sustained population suppression.
• Maintaining a fertility control program reduces the reproduction and therefore the risk of future population spikes.
• The company believes that the size of the rat control market is sufficient for its near-term focus.
• The company believes that ContraPest or Evolve are novel in the pest control industry.
• The company believes that its internal production capabilities allow it to meet current and anticipated demand through 2024.
• The company believes that ContraPest or Evolve consumption should not cause rats to become ill or change their behavior.

Industry Context

The document highlights the growing concerns about traditional rodenticides, including bioaccumulation and impact on non-target species, which creates an opportunity for SenesTech's fertility control products. The company is also addressing the pest industry's reluctance to adopt new technologies by focusing on end-user awareness and creating demand for its products.

Comparison to Industry Standards

• SenesTech's approach to rat control through fertility management is a departure from traditional methods that rely heavily on lethal rodenticides, setting it apart from companies like Bayer Environmental Science, BASF, and Syngenta, which primarily focus on chemical-based solutions.
• Unlike traditional rodenticide companies, SenesTech's products, ContraPest and Evolve, are designed to be non-lethal and target the reproductive systems of rats, which is a unique approach in the pest control market.
• While companies like Rentokil Initial and Rollins, Inc. offer integrated pest management services, SenesTech's focus is on providing fertility control products that can be incorporated into these programs, rather than offering the services themselves.
• The company's emphasis on non-toxic solutions aligns with the growing trend towards sustainable and environmentally friendly pest control methods, which is a contrast to the traditional chemical-heavy approach of many competitors.
• SenesTech's products are designed to minimize exposure hazard for non-targeted species, which is a key differentiator from traditional rodenticides that have been reported to affect other species within the food chain.

Legal Proceedings

• In November 2023, a legal matter was settled for $185,000.

Related Party Transactions

• During each of the years ended December 31, 2023 and 2022, $4,200 and $50,400, respectively, of cash payments were made to the Kito Impact Foundation of which the Chair of the board, serves as chief executive officer.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional capital.
• Employees may be affected by potential cost-cutting measures or changes in the company's operations.
• Customers may benefit from the company's innovative pest control solutions, but may also be affected by potential product misuses.
• Suppliers may be impacted by the company's financial challenges and potential changes in its supply chain.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company will continue to focus on marketing and sales of ContraPest.
• The company will explore strategic partnerships to penetrate additional target markets and geographical locations.
• The company will seek additional regulatory approvals for ContraPest and Evolve.
• The company will further develop its manufacturing processes to contain costs and scale to meet future demand.
• The company will continue product development of ContraPest and Evolve and advance its research and development activities.
• The company expects to introduce an additional product during 2024.

Key Dates

Keywords

fertility control, pest management, ContraPest, Evolve, rat control, rodenticides, integrated pest management, IPM, EPA, FIFRA, reverse stock split, financial results, regulatory approval, commercialization, market acceptance